Medicenna Therapeutics Corp.

MDNA.TOTSXHealthcare● Active

$0.44

$-0.02(-3.33%)

Market Cap$29900726

P/E Ratio—

52W High$1.97

52W Low$0.41

Avg Volume116K

Open$0.43

Beta1.85

Net Income Financials Revenue

Medicenna Therapeutics Corp. (MDNA.TO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

MDNA.TO · net income · updated Jun 8, 2026

Core profitability metrics

MDNA.TO · net income · margin · TTM · CAGR

Net income was −$11.8M for FY2025 (fiscal year ending 2025-03-31), up 53.6% year-over-year. Net profit margin was —. Based on available data, Medicenna Therapeutics Corp. has been profitable since at least 2023.

FY2025 Net Income−$11.8M▲ +53.6% YoY

Trailing 12M (TTM)−$13.0Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+53.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2023

▸ FMP /income-statement · Annual · MDNA.TO net income history · MDNA.TO profit margin

Annual net income data

MDNA.TO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$11.8M▲ +53.6%—$0

FY2024Loss−$25.5M▼ 1746.2%—$0

FY2023★ First Profit$1.5M▲ +106.8%—$0

FY2022Loss−$22.6M▼ 31.8%—$0

FY2021Loss−$17.2M▼ 106.8%—$0

Net income vs peers (Healthcare)

MDNA.TO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Medicenna Therapeutics Corp.YOU

MDNA.TO

−$11.8M+53.6%—

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Medicenna Therapeutics Corp. (MDNA.TO) reported net income of −$11.8M for FY2025 (fiscal year ending 2025-03-31), up 53.6% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Based on available data, Medicenna Therapeutics Corp. has been profitable since at least 2023. Net income reached a peak of $1.5M in FY2023. Data available for 12 fiscal years.

Medicenna Therapeutics Corp.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Medicenna Therapeutics Corp. net worth" — the company's market capitalization is a separate figure from MDNA.TO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

MDNA.TO net income · 4 questions

Medicenna Therapeutics Corp. is not currently profitable on an annual basis. The company reported a net loss of $11.8M for FY2025.

is MDNA.TO profitabledoes MDNA.TO make a profitMDNA.TO profitabilityMDNA.TO profitable company

▸ Source: FMP /income-statement · GAAP · Medicenna Therapeutics Corp. · Medicenna Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026